News
Chronic diseases, such as diabetes, cardiovascular conditions, autoimmune disorders, and cancer, represent an escalating global health challenge, exerting ...
As regulators push to phase out animal testing, Charles River’s Steve Bulera notes that widespread implementation of ...
Alpha1H shows benefit in non-muscle invasive bladder cancer, shrinking tumors and boosting the immune system with manageable ...
UCLA’s cancer research has been deeply impactful, with millions of people receiving drugs and therapies developed in Bruin ...
A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...
While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.
Correa and Bergman are co-chairs of the congressional Psychedelics Advancing Therapies (PATH) Caucus. Mercer is a Marine Corps veteran and the executive director of Healing Breakthrough.
Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment ...
New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small ...
Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc.
Linvoseltamab gains FDA approval as an effective off-the-shelf therapy for relapsed multiple myeloma, showcasing impressive response rates and safety profiles.
There is no cure for congenital erythropoietic porphyria, but after years of work and patient collaboration, a potential drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results